EASL2015:先天免疫和适应性免疫应答相关 聚乙二醇干扰素α治

StephenW

P0544
INNATE AND ADAPTIVE IMMUNE RESPONSES CORRELATE
WITH PEGINTERFERON ALFA TREATMENT EFFICACY IN CHRONIC
HEPATITIS B PATIENTS (THE OSST IMMUNOLOGY STUDY)
W. Yan1, D. Wu1, X. Wang1, Q. Lai2, Q. Zheng2, J. Jiang3, J. Hou2,
M. Han1, Q. Ning1. 1Department and Institute of Infectious Disease,
Tongji Hospital, Tongji Medical College, Huazhong University of
Science and Technology, Wuhan, 2Hepatology Unit and Department
of Infectious Diseases, Nanfang Hospital, Southern Medical University,
Guangzhou, 3Department of Liver Diseases Research Center, First
Affiliated Hospital of Fujian Medical University, Fuzhou, China
E-mail: [email protected]
Background and Aims: The aim of this study was to characterize
the immunological features responsible for improved treatment
responses in 77 patients with chronic hepatitis B (CHB) treated
with peginterferon (Peg IFN) alfa-2a after switching them from
entecavir (ETV) therapy.
Methods: Peripheral natural killer (NK) cells, Toll-like receptors
(TLRs), T cells, regulatory T cells (Tregs) and programmed death 1
(PD-1) were evaluated dynamically by flow cytometry. Response
was defined as hepatitis B e antigen (HBeAg) seroconversion,
hepatitis B surface antigen (HBsAg) loss, and HBsAg seroconversion
(either as singular events or in combination at week 48)
Results: From week 12 to week 24, compared with ETV responders
or Peg IFN alfa non-responders, Peg IFN alfa responders exhibited a
significant decline in Treg proportions as well as a diminished
negative regulation of CD8+ T cells by Tregs. Those HBeAgnegative
patients at baseline treated with Peg IFN alfa also showed
significantly decreased Treg proportions and a higher rate of
HBsAg seroconversion. Moreover, Peg IFN alfa responders showed
a significantly higher increase in the NKG2C+ NK cell proportions
from baseline to week 12 and of TLR2+ monocytes at week 12 than
Peg IFN alfa non-responders.
Conclusions: Successful response to Peg IFN alfa correlates with
an early significant restoration of impaired immune responses.
Although antiviral treatment response can be achieved by both
IFN and ETV, the underlying immunological features vary which
may explain the generally observed difference in off-treatment
durability of response between the two treatments, as well as
effects on HBsAg.
negative regulation of CD8+ T cells by Tregs. Those HBeAg negative
patients at baseline treated with Peg IFN alfa also showed
significantly decreased Treg proportions and a higher rate of
HBsAg seroconversion. Moreover, Peg IFN alfa responders showed
a significantly higher increase in the NKG2C+ NK cell proportions
from baseline to week 12 and of TLR2+ monocytes at week 12 than
Peg IFN alfa non-responders

StephenW

P0544
先天免疫和适应性免疫应答相关
聚乙二醇干扰素α治疗效果慢性
乙肝患者（THE OSST免疫学研究）
W.艳，D. WU1，X.旺1，问：来2，问：Zheng2，J. Jiang3，J. Hou2，
M. Han1，问：宁1。教研室和传染病研究所，
同济医院，同济医学院，华中科技大学
科技，武汉，2肝病单位和部门
传染病，南方医院，南方医科大学，
广州市肝病，3Department研究中心，第一
福建医科大学，福州，中国附属医院
电子邮件：[email protected]
背景和目的：本研究的目的是来表征
负责改进治疗的免疫功能
在77例慢性乙型肝炎的反应（CHB）治疗
与聚乙二醇干扰素（PEG IFN）从切换后他们干扰素α-2a
恩替卡韦（ETV）治疗。
方法：外围自然杀伤（NK）细胞，Toll样受体
（的TLR），T细胞，调节性T细胞（Treg细胞）和程序性死亡1
（PD-1），通过流式细胞术动态评估。响应
被定义为乙型肝炎e抗原（HBeAg）血清转换，
乙型肝炎表面抗原（HBsAg）的损失，与HBsAg阳转
（无论是作为单一事件或在48周联合）
结果：从12周〜24周，ETV反应比较
或PEG干扰素α无应答者，PEG干扰素α应答展出
在调节性T细胞的比例显著下降以及一个减弱
CD8 + T细胞的调节性T细胞通过负调控。这些HBeAgnegative
患者在基线用PEG干扰素α治疗也显示
显著下降Treg细胞比例和更高的速率
乙肝表面抗原血清学转换。此外，PEG干扰素α应答表现
在NKG2C + NK细胞的比例一显著增幅较高
从基线至TLR2的12周和+单核细胞在第12周比
PEG干扰素α无应答。
结论：成功应对钉干扰素α与关联
早期显著恢复受损的免疫应答。
尽管抗病毒治疗的反应可通过同时实现
IFN和ETV，底层的免疫功能而异
可以解释在非治疗的一般观察到的差异
两种治疗之间的反应的耐久性，以及
对HBsAg的影响。
CD8 + T细胞的调节性T细胞通过负调控。那些HBeAg阴性
患者在基线用PEG干扰素α治疗也显示
显著下降Treg细胞比例和更高的速率
乙肝表面抗原血清学转换。此外，PEG干扰素α应答表现
在NKG2C + NK细胞的比例一显著增幅较高
从基线至TLR2的12周和+单核细胞在第12周比
PEG干扰素α无应答